Japan Tissue Engineering Co., Ltd. (7774.T)
- Previous Close
627.00 - Open
620.00 - Bid 610.00 x --
- Ask 612.00 x --
- Day's Range
608.00 - 627.00 - 52 Week Range
361.00 - 780.00 - Volume
101,000 - Avg. Volume
284,887 - Market Cap (intraday)
24.813B - Beta (5Y Monthly) 0.25
- PE Ratio (TTM)
-- - EPS (TTM)
-1.76 - Earnings Date Apr 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1,200.00
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. is a subsidiary of Teijin Limited.
www.jpte.co.jpRecent News: 7774.T
View MorePerformance Overview: 7774.T
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 7774.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 7774.T
View MoreValuation Measures
Market Cap
25.46B
Enterprise Value
21.20B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.48
Price/Book (mrq)
4.35
Enterprise Value/Revenue
8.72
Enterprise Value/EBITDA
226.14
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.39%
Return on Assets (ttm)
-2.20%
Return on Equity (ttm)
-4.28%
Revenue (ttm)
2.46B
Net Income Avi to Common (ttm)
-255M
Diluted EPS (ttm)
-1.76
Balance Sheet and Cash Flow
Total Cash (mrq)
3.88B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-185.75M